154 related articles for article (PubMed ID: 12720152)
21. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
22. [IMiDs in hematology].
Wémeau M; Gauthier J; Leleu X; Yakoub-Agha I
Bull Cancer; 2011 Aug; 98(8):879-87. PubMed ID: 21827980
[TBL] [Abstract][Full Text] [Related]
23. Role of proteasome inhibition in Waldenström's macroglobulinemia.
Roccaro AM; Sacco A; Leleu X; Azab AK; Azab F; Runnels J; Jia X; Ngo HT; Melhem M; Moreau AS; Ghobrial IM
Clin Lymphoma Myeloma; 2009 Mar; 9(1):94-6. PubMed ID: 19362985
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide analogs as emerging anti-cancer drugs.
Dredge K; Dalgleish AG; Marriott JB
Anticancer Drugs; 2003 Jun; 14(5):331-5. PubMed ID: 12782937
[TBL] [Abstract][Full Text] [Related]
25. PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.
Sobhani M; Abdi J; Manujendra SN; Chen C; Chang H
Cancer Biol Ther; 2015; 16(5):799-806. PubMed ID: 25803193
[TBL] [Abstract][Full Text] [Related]
26. The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures.
Molostvov G; Morris A; Rose P; Basu S; Muller G
Br J Haematol; 2004 Feb; 124(3):366-75. PubMed ID: 14717786
[TBL] [Abstract][Full Text] [Related]
27. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Corral LG; Haslett PA; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G
J Immunol; 1999 Jul; 163(1):380-6. PubMed ID: 10384139
[TBL] [Abstract][Full Text] [Related]
28. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
[TBL] [Abstract][Full Text] [Related]
29. Involvement of p42/p44 MAPK, JNK, and NF-kappaB in IL-1beta-induced ICAM-1 expression in human pulmonary epithelial cells.
Lin FS; Lin CC; Chien CS; Luo SF; Yang CM
J Cell Physiol; 2005 Feb; 202(2):464-73. PubMed ID: 15389584
[TBL] [Abstract][Full Text] [Related]
30. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
31. JNK signaling involved in the effects of cyclic AMP on IL-1beta plus IFNgamma-induced inducible nitric oxide synthase expression in hepatocytes.
Zhang B; Perpetua M; Fulmer M; Harbrecht BG
Cell Signal; 2004 Jul; 16(7):837-46. PubMed ID: 15115662
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation.
Jimenez JL; Punzón C; Navarro J; Muñoz-Fernández MA; Fresno M
J Pharmacol Exp Ther; 2001 Nov; 299(2):753-9. PubMed ID: 11602691
[TBL] [Abstract][Full Text] [Related]
33. Dual regulation of tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition.
Chen YM; Chiang WC; Lin SL; Wu KD; Tsai TJ; Hsieh BS
J Pharmacol Exp Ther; 2004 Jun; 309(3):978-86. PubMed ID: 14978197
[TBL] [Abstract][Full Text] [Related]
34. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.
Reddy N; Hernandez-Ilizaliturri FJ; Deeb G; Roth M; Vaughn M; Knight J; Wallace P; Czuczman MS
Br J Haematol; 2008 Jan; 140(1):36-45. PubMed ID: 17995965
[TBL] [Abstract][Full Text] [Related]
36. Amyloidosis and Waldenström's macroglobulinemia.
Gertz MA; Merlini G; Treon SP
Hematology Am Soc Hematol Educ Program; 2004; ():257-82. PubMed ID: 15561687
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals.
Gutiérrez NC; Ocio EM; de Las Rivas J; Maiso P; Delgado M; Fermiñán E; Arcos MJ; Sánchez ML; Hernández JM; San Miguel JF
Leukemia; 2007 Mar; 21(3):541-9. PubMed ID: 17252022
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis in Waldenstrom's macroglobulinemia.
Rajkumar SV; Hayman S; Greipp PR
Semin Oncol; 2003 Apr; 30(2):262-4. PubMed ID: 12720149
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
40. CC-1088 Celgene.
Dredge K
Curr Opin Investig Drugs; 2005 May; 6(5):513-7. PubMed ID: 15912966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
